Globally, rapid population ageing is redefining public health needs, and age-related muscle decline - now recognised as a muscle disease - has become an urgent concern. Sarcopenia threatens mobility and independence, often setting off a chain of health challenges as muscle strength diminishes.
Weaker muscles greatly increase the risk of falls, one of the most serious causes of injury in older adults. A single fall can lead to fractures, hospitalisation, and long-term loss of independence, ultimately increasing reliance on care and adding strain to families and healthcare systems.
Rising rates of sarcopenia are driving strong consumer demand for evidence-based ingredients that go beyond protein, amino acids, and conventional sports formulas.
New human study: OliFuco® RE shows promising benefits
A newly published clinical trial suggests that OliFuco® RE supplementation, a new oligo fucoidan-derived ingredient, may offer a safe approach to improving muscle strength and physical performance in community-dwelling older adults.
The 12-week, randomised, double-blind, placebo-controlled clinical trial was conducted in community-dwelling adults aged 60 and above.
Key findings: meaningful gains in strength, mobility and protection
Participants receiving OliFuco® RE experienced:
- Significant improvement in grip strength (p < 0.001), representing a major functional gain for older adults.
- Enhanced walking performance, with nearly half exceeding clinically relevant thresholds in the six-minute walk test.
- Prevention of calf-circumference loss, suggesting protection against age-related muscle deterioration.
- Excellent safety and tolerability, with no adverse events reported.
OliFuco® RE’s ability to improve strength and physical performance positions it as a compelling nutraceutical active for muscle-health formulations, especially for brands serving senior wellness, mobility support, sport health, and functional nutrition categories.
